Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01557 |
| Species: | Homo sapiens |
| Position : | chr12:122502280-122506427 |
| Year: | 2023 |
| Title: | Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m6A modification |
| Genome Build: | hg38 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | prostate cancer |
| PMID: | 36632223 |
| MONDO: | MONDO:0008315 |
| Tissue: | Bone |
| Tissue Ontology ID: | UBERON:0001474 |
| Cell Source: | C4-2B |
| CVCL ID: | CVCL_4784 |
| Cell Type: | prostate carcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| High Throughput Method: | RNA-seq, MeRIP-seq, ChIP-seq, Capture Hi-C |
| Low Throughput Method: | 3C assay, CLIP, RT-RT-qPCR, Western blot |
| Target gene : | PSMD9 |
| TF name : |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|